SCHEMBL26098397

SCHEMBL26098397

O=C(NCc1ccc(F)c(F)c1)c1cc(Cl)ccc1O

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
P2RX1 P51575 3/20 0.64
TMPRSS4 Q9NRS4 2/20 0.64
TUBB P07437 2/20 0.58
CDK1 P06493 1/20 0.55
P2RX4 Q99571 1/20 0.51
P2RX7 Q99572 1/20 0.51
TAS1R3 Q7RTX0 1/20 0.51
TAS1R1 Q7RTX1 1/20 0.51
TAS1R2 Q8TE23 1/20 0.51
POLA1 P09884 2/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
PPARG P37231 2/20 0.50
MT-CO2 P00403 1/20 0.50
GSK3B P49841 1/20 0.49
LMNA P02545 1/20 0.49
HPGD P15428 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23675369 0.87 TMPRSS4 (0.67) P2RX1TMPRSS4TUBBCDK1P2RX4
SCHEMBL30100436 0.87 TMPRSS4 (0.67) P2RX1TMPRSS4TUBBCDK1P2RX4
SCHEMBL13812639 0.87 P2RX1 (0.66) P2RX1TMPRSS4TUBBCDK1P2RX4
SCHEMBL23675446 0.87 TUBB (0.72) P2RX1TMPRSS4TUBBCDK1P2RX4
SCHEMBL13812912 0.86 TMPRSS4 (0.68) P2RX1TMPRSS4TUBBCDK1P2RX4
SCHEMBL13812915 0.84 P2RX1 (0.70) P2RX1TMPRSS4TUBBCDK1P2RX4
SCHEMBL23675443 0.83 P2RX1 (0.64) P2RX1TMPRSS4TUBBCDK1P2RX4
SCHEMBL26097052 0.82 HPGD (0.63) P2RX1TMPRSS4TUBBCDK1POLA1
SCHEMBL13236587 0.81 TUBB (0.75) P2RX1TMPRSS4TUBBCDK1POLA1
SCHEMBL30100461 0.81 TUBB (0.75) P2RX1TMPRSS4TUBBCDK1POLA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230140290-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING THE BOARD OF REGENTS OF THE UNIV OF TEXAS SY (US) 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230140290-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING EIF2AK2, SARS1, ACE P2RX1 3088/4885TMPRSS4 526/4885TUBB 3158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.